| Literature DB >> 17521443 |
David E Goodrich1, Angela R Larkin, Julie C Lowery, Robert G Holleman, Caroline R Richardson.
Abstract
BACKGROUND: For high-risk individuals and their healthcare providers, finding the right balance between promoting physical activity and minimizing the risk of adverse events can be difficult. More information on the prevalence and influence of adverse events is needed to improve providers' ability to prescribe effective and safe exercise programs for their patients.Entities:
Year: 2007 PMID: 17521443 PMCID: PMC1891313 DOI: 10.1186/1479-5868-4-20
Source DB: PubMed Journal: Int J Behav Nutr Phys Act ISSN: 1479-5868 Impact factor: 6.457
Summary of study and non-study related adverse events symptoms
| Serious | 2 (1.4) | 46 (31.5) |
| Non-Serious | 17 (11.6) | 81 (55.5) |
Demographic characteristics of participants
| White/Hispanic | 182 | 66.9 |
| African American | 74 | 27.2 |
| Native American or Alaskan Native | 14 | 5.1 |
| Asian | 1 | 0.4 |
| Pacific Hawaiian or other Pacific Islander | 1 | 0.4 |
| Not given | 5 | 1.8 |
| Less than High School | 10 | 3.7 |
| High School Graduate | 43 | 15.8 |
| Some College | 128 | 47.1 |
| College Graduate | 63 | 23.2 |
| Graduate School | 28 | 10.3 |
| < $20,000 | 89 | 32.7 |
| $20,000 – $39,999 | 71 | 26.1 |
| $40,000 – $59,999 | 46 | 16.9 |
| $60,000 – $80,000 | 31 | 11.4 |
| > $80,000 | 26 | 9.6 |
| Not given | 11 | 4.0 |
| 44 | 16.9 | |
| 36.1 ± 5.3 |
* Total frequency exceeds 100% due to three individuals who endorsed two or more ethnicities.
** Missing data for two individuals reduced enrolled sample n to 272 for this descriptive analysis.
† Analysis based on N = 274.
Participant baseline health characteristics at baseline assessment
| Very Good to Excellent | 39 | 14.2 |
| Good | 111 | 40.5 |
| Poor to Fair | 99 | 40.9 |
| Not given | 10 | 4.4 |
| Hypertension | 192 | 70.6 |
| High Cholesterol | 178 | 65.4 |
| Depression, anxiety, or other mood disorder | 159 | 58.5 |
| Osteoarthritis | 142 | 52.2 |
| Diabetes | 121 | 44.5 |
| Sleep disorders | 118 | 43.4 |
| Chronic pain | 117 | 43.0 |
| Hearing problems | 95 | 34.9 |
| Angina | 63 | 23.2 |
| Lung disease, emphysema, asthma, or bronchitis | 58 | 21.3 |
| Heart Attack | 34 | 12.5 |
| Cataracts | 34 | 12.5 |
| Cancer (non-skin) | 24 | 8.8 |
| Congestive Heart Failure | 22 | 8.1 |
| Stroke | 18 | 6.6 |
| Hip or knee joint replacement surgery | 18 | 6.6 |
| Glaucoma | 14 | 5.1 |
| Osteoporosis | 14 | 5.1 |
| Parkinson's disease | 1 | 0.4 |
| 5.2 ± 2.3 |
* Missing data for two individuals reduced enrolled sample n to 272 for this descriptive analysis.
Clinical typology of adverse events symptoms
| High/Low blood pressure | 32 |
| Angina/Chest tightness | 9 |
| Orthopnea, low extremity edema | 7 |
| Shortness of breath | 9 |
| Light-headedness, dizziness | 12 |
| Diaphoresis | 2 |
| Stroke, myocardial infarction | 2 |
| Other CVD | 1 |
| Sudden weight gain | 3 |
| Hypo-, Hyperglycemia | 5 |
| Hypo-, Hyperkalemia | 2 |
| Neuro-motor | 4 |
| Mood Disorder | 4 |
| Laceration, scrape, bruises | 3 |
| Muscle pulls, strains, sprains, soreness | 13 |
| Bone or joint trauma/fracture | 11 |
| Gastric reflux | 1 |
| Rectal bleeding | 2 |
| Dermatological (fungus, blister, boil) | 4 |
| Viral, bacterial, fungal, or insect | 11 |
Note. These symptoms represent 121 individual adverse event reports from 87 separate individuals. Thus, multiple symptoms could be reported on an individual report and some participants experienced 2 (n = 24) or 3 (n = 5) adverse events during the trial period summarized for this study.
Classification of adverse events by cause and relatedness to study intervention
Note. Serious AE's were defined consistent with most IRB definitions as a 1) death; 2) a life threatening experience; 3) hospitalization or prolongation of hospitalization; 4) persistent significant disability or incapacity; or 5) an event that jeopardizes the subject and may require medical or surgical treatment to prevent one of the preceding outcomes. Non-serious AE's consisted of both minor and moderately serious AE's. Moderately serious AE's were defined as concerning new medical symptoms (not imminently life threatening) or acute events that either required suspension until clearance by a physician to rule out potential for Serious AE's (cardiopulmonary dysfunction) and insure optimal patient self-care (e.g., medication, blood pressure, or blood sugar regulation) or, events causing voluntary cessation of walking by the participant until the aggravating event passed (e.g., illness, serious musculoskeletal injury, motor vehicle accident). Minor AE's were defined as events not necessitating study suspension and causing minor discomfort or inconvenience to the participant as a result of study participation (e.g., sore muscles, blisters, equipment malfunction).